In late July 2026, the radiology artificial intelligence space received a notable boost when CARPL.ai announced a Series A funding round of ten million dollars. The round was led by the International Finance Corporation, the private sector arm of the World Bank Group, with participation from Stellaris Venture Partners and other investors. The development marks a significant milestone for the company, which has built a vendor neutral platform connecting healthcare providers with a wide range of imaging AI tools.
Founded in 2021, CARPL.ai positions itself as the world’s largest radiology AI marketplace and enterprise platform. It currently offers more than three hundred AI applications from over one hundred partners. Through a single integration, hospitals and radiology groups can discover, test, deploy, and monitor these solutions within their existing clinical workflows. The platform works with leading PACS systems and remains infrastructure agnostic, addressing the long standing challenge of fragmented AI adoption in medical imaging.
Medical imaging accounts for a substantial share of healthcare data, yet putting AI tools into daily practice has remained complex for many institutions. CARPL.ai aims to simplify this process by serving as a governance and procurement layer. The platform has already gained the trust of major healthcare organisations, including several of the largest private radiology groups, and is used by government entities in countries such as Brazil, India, Singapore, Spain and the United Arab Emirates.
Dr Vidur Mahajan, CEO of CARPL.ai, highlighted the company’s progress in recent years. He noted that the team has built deep integrations with enterprise PACS providers and earned the confidence of large healthcare enterprises that now rely on the platform for their AI journeys. The new capital, he said, will help accelerate the mission of enabling clinicians to use the best available AI technology for their patients in a safe and meaningful way. Looking ahead, the company plans to expand beyond radiology into other clinical areas such as pathology and genomics.
The International Finance Corporation’s Farid Fezoua emphasised the broader impact of the investment. He pointed to the role of AI in improving diagnostic quality and expanding access to care, particularly in emerging markets. The partnership also reflects support for India’s technology talent, with the company building high skill capabilities in engineering, product development and AI that serve global markets.
Alok Goyal of Stellaris Venture Partners, an earlier investor, expressed continued confidence in the team’s execution. Since the initial investment, CARPL.ai has earned recognition as a KPMG US Tech Innovator, been named Economic Times Health Tech Startup of the Year, and featured among YourStory’s Tech30 pioneers. It was also one of only three Indian AI startups selected to present its platform to Bill Gates.
The fresh funds will support product innovation, growth of the partner ecosystem, and commercial expansion across North America, Latin America, Europe, Asia Pacific and other emerging markets. As healthcare systems worldwide continue to explore AI for faster and more accurate diagnostics, platforms like CARPL.ai are working to turn technical promise into practical, scalable solutions for everyday clinical use.
